Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): A report from the Children's Oncology Group

Blood

Volumn 113, Issue 26, 2009, Pages 6558-6566

  Ho, Phoenix A ^a,b   Alonzo, Todd A ^c,d   Gerbing, Robert B ^d   Pollard, Jessica ^a,b,d   Stirewalt, Derek L ^a   Hurwitz, Craig ^e   Heerema, Nyla A ^f   Hirsch, Betsy ^g   Raimondi, Susana C ^h   Lange, Beverly ⁱ   Franklin, Janet L ^j   Radich, Jerald P ^a   Meshinchi, Soheil ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e Maine Children's Cancer Program Portland   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^h ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^j CHILDREN S HOSPITAL LOS ANGELES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; MITOXANTRONE; CCAAT ENHANCER BINDING PROTEIN; CEBPA PROTEIN, HUMAN; DNA; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; BASIC LEUCINE ZIPPER MOTIF; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CHILD; CHILDHOOD CANCER; CHROMOSOME ANALYSIS; CLINICAL FEATURE; DNA POLYMORPHISM; EVENT FREE SURVIVAL; FEMALE; GENE MUTATION; HUMAN; INFANT; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; TREATMENT OUTCOME; ACUTE DISEASE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETIC POLYMORPHISM; GENETICS; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; MYELOID LEUKEMIA; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; RETROSPECTIVE STUDY; STATISTICS;

ACUTE DISEASE; ADOLESCENT; CCAAT-ENHANCER-BINDING PROTEINS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; INFANT; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID; MALE; NEOPLASM PROTEINS; POLYMORPHISM, GENETIC; PREVALENCE; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 69249229646     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-10-184747     Document Type: Article

References (42)

1. Lekstrom-Himes J, Xanthopoulos KG. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J Biol Chem. 1998;273: 28545-28548. (Pubitemid 28507532)
2. Pabst T, Mueller BU, Zhang P, Radomska HS, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPα), in acute myeloid leukemia. Nat Genet. 2001;27:263-270. (Pubitemid 32201846)
3. Gombart AF, Hofmann WK, Kawano S, et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood. 2002;99:1332-1340. (Pubitemid 34547089)
4. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial: The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333.
5. Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood. 1999; 94:3707-3716.
6. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752-1759.
7. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326-4335. (Pubitemid 34627197)
8. Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97:89-94. (Pubitemid 32061246)
9. Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108:3654-3661. (Pubitemid 44864541)
10. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005; 352:254-266. (Pubitemid 40110814)
11. Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106:3740-3746. (Pubitemid 41739007)
12. Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106:3747-3754.
13. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107:4011-4020. (Pubitemid 43726809)
14. Brown P, McIntyre E, Rau R, et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood. 2007;110:979-985. (Pubitemid 47267437)
15. Graves BJ, John PH, McKnight SL. Homologous recognition of a promoter domain common to the MSV LTR and the HSV tk gene. Cell. 1986;44: 565-576.
16. Johnson PF, Landschulz WH, Graves BJ, et al. Identification of a rat liver nuclear protein that binds to the enhancer core element of three animal viruses. Genes Dev. 1987;1:133-146.
17. Landschulz WH, Johnson PF, McKnight SL. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science. 1988;240:1759-1764.
18. Friedman AD, McKnight SL. Identification of two polypeptide segments of CCAAT/enhancerbinding protein required for transcriptional activation of the serum albumin gene. Genes Dev. 1990;4:1416-1426. (Pubitemid 20262557)
19. Lin FT, MacDougald OA, Diehl AM, et al. A 30- kDa alternative translation product of the CCAAT/ enhancer binding protein alpha message: transcriptional activator lacking antimitotic activity. Proc Natl Acad Sci U S A. 1993;90:9606-9610. (Pubitemid 23315834)
20. Rosen ED, Hsu CH, Wang X, et al. C/EBPα induces adipogenesis through PPARγ: a unified pathway. Genes Dev. 2002;16:22-26. (Pubitemid 34049634)
21. Flodby P, Barlow C, Kylefjord H, et al. Increased hepatic cell proliferation and lung abnormalities in mice deficient in CCAAT/enhancer binding protein alpha. J Biol Chem. 1996;271:24753-24760. (Pubitemid 26333221)
22. Martis PC, Whitsett JA, Xu Y, et al. C/EBPα is required for lung maturation at birth. Development. 2006;133:1155-1164.
23. Tenen DG, Hromas R, Licht JD, et al. Transcription factors, normal myeloid development, and leukemia. Blood. 1997;90:489-519. (Pubitemid 27299089)
24. Porse BT, Pedersen TA, Xu X, et al. E2F repression by C/EBPα is required for adipogenesis and granulopoiesis in vivo. Cell. 2001;107:247-258. (Pubitemid 33035950)
25. Johansen LM, Iwama A, Lodie TA, et al. c-Myc is a critical target for C/EBPα in granulopoiesis. Mol Cell Biol. 2001;21:3789-3806. (Pubitemid 32466991)
26. Radomska HS, Huettner CS, Zhang P, et al. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol. 1998;18:4301-4314. (Pubitemid 28287953)
27. Nerlov C. C/EBPα mutations in acute myeloid leukaemias. Nat Rev Cancer. 2004;4:394-400. (Pubitemid 38579485)
28. Lin LI, Chen CY, Lin DT, et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res. 2005;11:1372-1379.
29. Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002;100:2717-2723.
30. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, Meijer J, et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J. 2003;4:31-40. (Pubitemid 36927158)
31. Fröhling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004;22:624-633. (Pubitemid 41095065)
32. Liang DC, Shih LY, Huang CF, et al. CEBPα mutations in childhood acute myeloid leukemia. Leukemia. 2005;19:410-414. (Pubitemid 40403318)
33. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a Children's Oncology Group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Blood. 2008;111:1044-1053. (Pubitemid 351213382)
34. Wouters BJ, Louwers I, Valk PJ, et al. A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML. Blood. 2007;109:389-390. (Pubitemid 46053086)
35. Biggio V, Renneville A, Nibourel O, et al. Recurrent in-frame insertion in C/EBPα TAD2 region is a polymorphism without prognostic value in AML. Leukemia. 2008;22:655-657.
36. Kirstetter P, Schuster MB, Bereshchenko O, et al. Modeling of C/EBPα mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell. 2008;13:299-310.
37. Smith ML, Cavenagh JD, Lister TA, et al. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med. 2004;351:2403-2407. (Pubitemid 40500184)
38. Sellick GS, Spendlove HE, Catovsky D, et al. Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia. Leukemia. 2005;19:1276-1278. (Pubitemid 40946018)
39. Tiesmeier J, Czwalinna A, Muller-Tidow C, et al. Evidence for allelic evolution of C/EBPα mutations in acute myeloid leukaemia. Br J Haematol. 2003;123:413-419. (Pubitemid 37363480)
40. Shih LY, Liang DC, Huang CF, et al. AML patients with CEBPα mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: a comparative analysis on paired diagnosis and relapse samples. Leukemia. 2006;20:604-609.
41. Pollard JA, Alonzo TA, Gerbing RB, et al. FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia. Blood. 2006;108:2764-2769. (Pubitemid 44777014)
42. Koschmieder S, D'Alo F, Radomska H, et al. CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational upregulation of p42 CCAAT enhancer binding protein alpha. Blood. 2007;110:3695-3705.